GSK Consumer Healthcare to prioritize digital after agency review

Now that it has consolidated its global agency roster, GSK Consumer Healthcare aims to increase digital marketing efforts.

As immuno-oncology therapies evolve, so will the marketing

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Huntsworth Health revenue rose 18% in the first half of 2016

Huntsworth Health revenue rose 18% in the first half of 2016

Red, a Huntsworth agency, also counted Sanofi as a new client.

M Booth supports Leukemia & Lymphoma Society's Light the Night campaign

M Booth supports Leukemia & Lymphoma Society's Light the Night campaign

The nonprofit is dedicated to curing blood cancer.

Five things for pharma marketers to know: Monday, July 25, 2016

Five things for pharma marketers to know: Monday, July 25, 2016

Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting

CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Biogen ends Tecfidera DTC campaign, citing prescriptions

Biogen ends Tecfidera DTC campaign, citing prescriptions

The drugmaker had launched the campaign for the multiple sclerosis drug in 2015.

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

Novartis ups marketing investment in Entresto, by $200 million

Novartis ups marketing investment in Entresto, by $200 million

One oft-cited challenge to Entresto's adoption has been prior authorization requirements.

Why competing agencies are joining forces to give parents more time off

Why competing agencies are joining forces to give parents more time off

Twenty shops, including Co:Collective, Wolff Olins, and 72andSunny, have signed onto the Pledge Parental Leave coalition since March.

Five things for pharma marketers to know: Tuesday, July 19, 2016

Five things for pharma marketers to know: Tuesday, July 19, 2016

The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants

ZS' Pete Mehr on embracing and adapting to change

ZS' Pete Mehr on embracing and adapting to change

Mehr was recently promoted to lead customer-centric marketing solutions at ZS Associates.

Five things for pharma marketers to know: Monday, July 18, 2016

Five things for pharma marketers to know: Monday, July 18, 2016

Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages

Agency Spotlight


OPINION

Email Newsletters